Can You Advertise GLP-1s on Meta?

What this means for you

• Weight loss ads must target people 18 or older, and that restriction sits on the ad set, not only on the creative.
• Copy that asserts or implies the viewer's health status or body is prohibited under the personal attributes policy, whatever the imagery.
• Since July 22, 2026 before-and-after imagery is not banned on its own; the claims around it decide the outcome. Pinched-fat close-ups, statements of inferiority and outcome promises within a set timeframe without a disclaimer still fail.
• Promoting a prescription GLP-1 product by name requires active LegitScript certification and Meta's prescription-drug authorization. Promoting a telehealth service in general terms does not.
• Disapproval rate is the number to watch, because a pattern of disapprovals is what escalates to a restricted account.

The short answer

Meta permits advertising for weight loss products and services to audiences aged 18 and over, and GLP-1 telehealth brands can and do run compliant campaigns at scale. MedScale, which builds patient acquisition for telehealth companies exclusively, sees the difficulty as structural rather than incidental: the creative conventions that perform best in direct-response marketing are the exact conventions Meta's health policies prohibit. That is why the category carries an unusually high disapproval rate even among advertisers acting in good faith.

MedScale treats that gap as the core design constraint for GLP-1 campaigns rather than an obstacle to work around after launch. Creative is structured against the policy from the first concept, because reworking rejected creative after a disapproval pattern has already formed is far more expensive than designing for review up front.

What Meta actually prohibits in GLP-1 advertising

Three policy families govern this category, and GLP-1 advertisers collide with all three:

• Personal attributes. Ad copy must not assert or imply knowledge of a person's physical characteristics or health status. Second-person copy addressed to the reader's body is the most common violation in the category.
• Health and wellness claims. Statements of inferiority about appearance, close-ups pinching fat, and clickbait framing such as promised outcomes within a set timeframe without a disclaimer are prohibited. Since July 22, 2026 a before-and-after image is judged by these claims rather than rejected on sight.
• Prescription drugs. Naming or promoting a prescription GLP-1 product engages the Drugs and Pharmaceuticals policy: LegitScript certification, Meta authorization, a consult-a-professional disclaimer, and targeting limited to eligible countries and adults.

The age restriction sits on top of these: weight loss advertising must be limited to audiences 18 and over, and the restriction applies to the ad set, not only to the creative.

Why second-person copy is the most common cause of disapproval

The personal attributes rule is where most GLP-1 creative fails, and the reason is that direct-response copywriting is built on exactly the move the policy forbids. A line such as "Struggling with your weight?" addressed directly to the reader implies that the advertiser knows something about that reader's health. Meta reads that as an assertion about a personal attribute, regardless of intent.

The workable alternative is to move the subject of the sentence off the reader and onto the program. MedScale writes GLP-1 creative in brand voice describing what the program is and how it works, rather than in second person describing what the reader supposedly experiences. The message survives review, and in most cases it also reads less like a diagnosis, which matters for a category where trust drives conversion.

Disapproval versus account restriction: the distinction that matters most

A disapproval is a single ad rejected at review. An account restriction is an enforcement action against the advertising account itself, and it is what actually threatens a telehealth business.

The two are connected. Individual disapprovals are routine and recoverable. A sustained pattern of them is what escalates, because repeated violations against the same account signal to Meta's systems that the advertiser is not operating within policy. Escalation can extend beyond a single ad account to linked assets in the same Business Manager, which is why the consequences of a bad quarter are rarely contained to one campaign.

MedScale therefore treats disapproval rate as a leading risk indicator rather than a routine cost of doing business. A campaign clearing volume targets while accumulating rejections is not succeeding; it is borrowing against the account.

Creative structures that pass review

Four structural choices carry most of the compliance load in this category:

• Brand-voice framing instead of second-person address, so no sentence asserts anything about the viewer.
• Program and process imagery, including clinician consultations, packaging, and the intake experience, in place of body imagery of any kind.
• Mechanism-led copy that explains how the program works and who is eligible, rather than outcome-led copy promising a result.
• Testimonials describing the experience of the program, such as convenience, clinician access, or adherence, rather than physical transformation.

The landing page is reviewed as part of the ad

Meta evaluates the destination, not only the creative. A compliant ad pointing at a landing page with before-and-after imagery or guaranteed-outcome claims can be rejected on the basis of the page. Telehealth brands frequently miss this because the ad and the site are owned by different teams.

This is also where compounded GLP-1 claims most often create exposure, since landing pages tend to carry the detailed product language that the ad itself avoids. MedScale audits the destination alongside the creative for that reason.

What to do if the account is already restricted

The instinct to open a fresh Business Manager on the same domain and payment method is the single most damaging response available. Meta associates assets, and a replacement account built on the same identifiers is likely to inherit the enforcement rather than escape it, while adding evasion to the original problem.

The productive sequence is to identify the disapproval pattern that triggered the action, correct the underlying creative and landing pages, and only then appeal. An appeal filed while the offending assets are still live tends to confirm the original finding.

What changed in 2026

Two changes on Meta's own policy pages matter for this category. On July 22, 2026 the Health and Wellness policy was updated: it now states that ads for weight loss products and services targeted to adults can illustrate people using the product or service and its impact, and clearly indicate the time taken to achieve noticeable results, and it lists cosmetic procedures depicting before-and-after transformation as permitted. The prohibitions that remain are statements of inferiority about appearance, pinched-fat close-ups, cure claims for listed conditions, and sensational outcome promises without disclaimers or qualifiers.

The second is the Drugs and Pharmaceuticals policy, which the Health and Wellness page points to for weight loss products that require a prescription. Online pharmacies and telehealth providers must be actively certified with LegitScript and authorized by Meta before running ads that promote a prescription drug, may only target the United States, Canada and New Zealand, and only adults. Ads that promote telehealth services generally, without promoting the drug, need no authorization. MedScale reads that split as the line between a brand campaign and a product campaign, and structures accounts so the two never share an ad set.

Compounded versus branded GLP-1 naming

Naming branded medications such as Ozempic, Wegovy, or Zepbound introduces trademark exposure on top of advertising policy, and compounded formulations carry a separate and shifting regulatory position. Both sit outside the scope of this page and are addressed separately.